Strangvac, a vaccine against equine strangles, is now available for sale in the UK

Stockholm, August 17th 2022 - Intervacc AB (publ) announces today that Strangvac is now available for sale in the UK.

This week Strangvac has been launched in the UK and horse owners can now vaccinate their horses against the infectious equine disease Strangles. Dechra will be distributing the vaccine in the UK and in a number of European countries.

"Strangles is highly contagious and is one of the most common equine infectious diseases with an estimated 600 outbreaks each year in the UK alone. Feared by many horse owners due to the potential severity of the clinical signs and the speed at which it can spread through an affected farm, we are sure the new strangles vaccine will be a vital tool and a huge benefit to the equestrian industry as a whole" says Sara Barker, equine field support manager at Dechra Pharmaceuticals PLC.

"Strangvac is approved for sale and marketing in the EU as well as the UK, Norway and Iceland, and has been launched in Sweden, Denmark and now also in the UK. The UK is expected to be one of the largest markets in Europe for a vaccine against this highly contagious infectious disease of horses" comments Andreas Andersson, CEO of Intervacc.

For more information please contact:  

Andreas Andersson, CEO

Phone: [phone], cell [phone]
E-mail: [e-mail]

The information was submitted for publication, through the agency of the contact person set out above on August 17, 2022, 13.00 CET.

About Intervacc

Intervacc AB is a Swedish company within animal health developing safe, effective vaccines for animals. The Company's vaccine and vaccine candidates are based on several years of research at Karolinska Institutet and Swedish University of Agricultural Research where the foundation was laid for the Company´s research and development work. The Intervacc share has been listed on the Nasdaq First North Growth Market since April 2017 with Eminova Fondkommission AB, [e-mail], [phone] as Certified Adviser.

About Dechra

Dechra is a global specialist veterinary pharmaceuticals and related products business. Dechra's expertise is in the development, manufacture marketing and sales of high quality products exclusively for veterinarians worldwide.  For more information, please visit: www.dechra.com

Stock Code: Full Listing (Pharmaceuticals): DPH , LEI: 213800J4UVB5OWG8VX82

 

About equine strangles

Equine strangles, caused by Streptococcus equi, is the most frequently diagnosed infectious disease of horses, and affects horses all over the world with one exception Iceland where the import of horses is prohibited. Streptococcus equi invades the lymph nodes of head and neck, causing them to swell and form abscesses that can literally strangle, in around 2% of cases, the horse to death. Some of the horses that recover from strangles remain persistently infected. These apparently healthy animals shed bacteria into the environment and spread the disease to other horses with which they come into contact.

 

Contact information for Certified Adviser

Eminova Fondkommission AB

E-mail: [e-mail], Phone: +46 (0)8 - 684 211 10

https://news.cision.com/intervacc/r/strangvac--a-vaccine-against-equine-strangles--is-now-available-for-sale-in-the-uk,c3615435

https://mb.cision.com/Main/4632/3615435/1615701.pdf

https://news.cision.com/intervacc/i/lntervacc-,c3078820

(c) 2022 Cision. All rights reserved., source Press Releases - English